欧洲现实世界中轴性脊柱炎和银屑病关节炎患者的四年secukinumab治疗结果

IF 3.8 3区医学 Q1 RHEUMATOLOGY

Joint Bone Spine Pub Date : 2024-11-26 DOI:10.1016/j.jbspin.2024.105824

Marion Pons , Stylianos Georgiadis , Mikkel Østergaard , Zohra Faizy Ahmadzay , Bente Glintborg , Jette Heberg , Sara Nysom Christensen , Simon Rasmussen , Anne Gitte Loft , Isabel Castrejón , Fernando Sánchez-Alonso , Florenzo Iannone , Dan Nordström , Anna-Mari Hokkanen , Adrian Ciurea , Michael J. Nissen , Jakub Závada , Karel Pavelka , Ziga Rotar , Katja Perdan Pirkmajer , Lykke Midtbøll Ørnbjerg

{"title":"欧洲现实世界中轴性脊柱炎和银屑病关节炎患者的四年secukinumab治疗结果","authors":"Marion Pons , Stylianos Georgiadis , Mikkel Østergaard , Zohra Faizy Ahmadzay , Bente Glintborg , Jette Heberg , Sara Nysom Christensen , Simon Rasmussen , Anne Gitte Loft , Isabel Castrejón , Fernando Sánchez-Alonso , Florenzo Iannone , Dan Nordström , Anna-Mari Hokkanen , Adrian Ciurea , Michael J. Nissen , Jakub Závada , Karel Pavelka , Ziga Rotar , Katja Perdan Pirkmajer , Lykke Midtbøll Ørnbjerg","doi":"10.1016/j.jbspin.2024.105824","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>In axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating secukinumab, we aimed to assess retention rates and proportions of patients achieving remission and low disease activity (LDA), according to disease activity measures and patient-reported outcomes at 24 and 48 months.</div></div><div><h3>Patients and methods</h3><div>Data on patients with axSpA and PsA who initiated secukinumab treatment were pooled from 13 European registries. Analyses were performed overall and stratified according to the number of previous biologic/targeted synthetic Disease-Modifying Antirheumatic Drugs (b/tsDMARDs, 0/1/≥2). Kaplan-Meier plots and Cox regression analyses were performed to assess and compare secukinumab retention rates. Comparisons of remission and LDA rates were performed by logistic regression analyses.</div></div><div><h3>Results</h3><div>The overall 24-/48-month secukinumab retention rates were 61%/51% in 767 axSpA patients, and 64%/49% in 975 PsA patients, respectively. Compared to b/tsDMARD naïve patients, a higher risk of withdrawal from secukinumab was found for those with≥2 prior b/tsDMARDs in axSpA and PsA, and 1 prior b/tsDMARD in axSpA. Generally, remission and LDA rates were numerically higher in b/tsDMARD naïve patients. After adjustment for confounders, statistically significantly higher remission and LDA rates were found for b/tsDMARD naïve patients compared to patients with≥ 2 prior b/tsDMARDs at 24 months in axSpA and PsA.</div></div><div><h3>Conclusion</h3><div>This large European real-world study demonstrates that 4-year secukinumab retention rates were approximately 50% in both axSpA and PsA. b/tsDMARD naïve patients had higher retention, remission and LDA rates than patients with prior b/tsDMARD exposure.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 3","pages":"Article 105824"},"PeriodicalIF":3.8000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis\",\"authors\":\"Marion Pons , Stylianos Georgiadis , Mikkel Østergaard , Zohra Faizy Ahmadzay , Bente Glintborg , Jette Heberg , Sara Nysom Christensen , Simon Rasmussen , Anne Gitte Loft , Isabel Castrejón , Fernando Sánchez-Alonso , Florenzo Iannone , Dan Nordström , Anna-Mari Hokkanen , Adrian Ciurea , Michael J. Nissen , Jakub Závada , Karel Pavelka , Ziga Rotar , Katja Perdan Pirkmajer , Lykke Midtbøll Ørnbjerg\",\"doi\":\"10.1016/j.jbspin.2024.105824\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><div>In axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating secukinumab, we aimed to assess retention rates and proportions of patients achieving remission and low disease activity (LDA), according to disease activity measures and patient-reported outcomes at 24 and 48 months.</div></div><div><h3>Patients and methods</h3><div>Data on patients with axSpA and PsA who initiated secukinumab treatment were pooled from 13 European registries. Analyses were performed overall and stratified according to the number of previous biologic/targeted synthetic Disease-Modifying Antirheumatic Drugs (b/tsDMARDs, 0/1/≥2). Kaplan-Meier plots and Cox regression analyses were performed to assess and compare secukinumab retention rates. Comparisons of remission and LDA rates were performed by logistic regression analyses.</div></div><div><h3>Results</h3><div>The overall 24-/48-month secukinumab retention rates were 61%/51% in 767 axSpA patients, and 64%/49% in 975 PsA patients, respectively. Compared to b/tsDMARD naïve patients, a higher risk of withdrawal from secukinumab was found for those with≥2 prior b/tsDMARDs in axSpA and PsA, and 1 prior b/tsDMARD in axSpA. Generally, remission and LDA rates were numerically higher in b/tsDMARD naïve patients. After adjustment for confounders, statistically significantly higher remission and LDA rates were found for b/tsDMARD naïve patients compared to patients with≥ 2 prior b/tsDMARDs at 24 months in axSpA and PsA.</div></div><div><h3>Conclusion</h3><div>This large European real-world study demonstrates that 4-year secukinumab retention rates were approximately 50% in both axSpA and PsA. b/tsDMARD naïve patients had higher retention, remission and LDA rates than patients with prior b/tsDMARD exposure.</div></div>\",\"PeriodicalId\":54902,\"journal\":{\"name\":\"Joint Bone Spine\",\"volume\":\"92 3\",\"pages\":\"Article 105824\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-11-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Joint Bone Spine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1297319X24001350\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Joint Bone Spine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1297319X24001350","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：在启动secukinumab的轴性脊柱炎（axSpA）和银屑病关节炎（PsA）患者中，我们的目标是根据疾病活动性测量和患者报告的24个月和48个月的结果，评估患者的保留率和达到缓解和低疾病活动性（LDA）的患者比例。患者和方法：开始secukinumab治疗的axSpA和PsA患者的数据来自13个欧洲注册中心。根据既往生物/靶向合成抗风湿药物（b/tsDMARDs, 0/1/≥2）的数量进行总体和分层分析。Kaplan-Meier图和Cox回归分析评估和比较secukinumab保留率。通过logistic回归分析比较缓解率和LDA率。结果：767例axSpA患者24 /48个月的整体secukinumab保留率为61%/51%，975例PsA患者为64%/49%。与b/tsDMARD naïve患者相比，先前在axSpA和PsA中有≥2个b/tsDMARD，在axSpA中有1个b/tsDMARD的患者有更高的停药风险。一般来说，b/tsDMARD naïve患者的缓解率和LDA率在数字上更高。校正混杂因素后，在24个月时，与既往b/tsDMARD≥2例的患者相比，b/tsDMARD naïve患者的缓解率和LDA率具有统计学意义。结论：这项大型欧洲现实世界研究表明，axSpA和PsA的4年secukinumab保留率均约为50%。b/tsDMARD naïve患者的保留率、缓解率和LDA率高于先前暴露于b/tsDMARD的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis

Objectives

In axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating secukinumab, we aimed to assess retention rates and proportions of patients achieving remission and low disease activity (LDA), according to disease activity measures and patient-reported outcomes at 24 and 48 months.

Patients and methods

Data on patients with axSpA and PsA who initiated secukinumab treatment were pooled from 13 European registries. Analyses were performed overall and stratified according to the number of previous biologic/targeted synthetic Disease-Modifying Antirheumatic Drugs (b/tsDMARDs, 0/1/≥ 2). Kaplan-Meier plots and Cox regression analyses were performed to assess and compare secukinumab retention rates. Comparisons of remission and LDA rates were performed by logistic regression analyses.

Results

The overall 24-/48-month secukinumab retention rates were 61%/51% in 767 axSpA patients, and 64%/49% in 975 PsA patients, respectively. Compared to b/tsDMARD naïve patients, a higher risk of withdrawal from secukinumab was found for those with ≥ 2 prior b/tsDMARDs in axSpA and PsA, and 1 prior b/tsDMARD in axSpA. Generally, remission and LDA rates were numerically higher in b/tsDMARD naïve patients. After adjustment for confounders, statistically significantly higher remission and LDA rates were found for b/tsDMARD naïve patients compared to patients with ≥ 2 prior b/tsDMARDs at 24 months in axSpA and PsA.

Conclusion

This large European real-world study demonstrates that 4-year secukinumab retention rates were approximately 50% in both axSpA and PsA. b/tsDMARD naïve patients had higher retention, remission and LDA rates than patients with prior b/tsDMARD exposure.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Joint Bone Spine 医学-风湿病学

CiteScore

4.50

自引率

11.90%

发文量

184

审稿时长

25 days

期刊介绍： Bimonthly e-only international journal, Joint Bone Spine publishes in English original research articles and all the latest advances that deal with disorders affecting the joints, bones, and spine and, more generally, the entire field of rheumatology. All submitted manuscripts to the journal are subjected to rigorous peer review by international experts: under no circumstances does the journal guarantee publication before the editorial board makes its final decision. (Surgical techniques and work focusing specifically on orthopedic surgery are not within the scope of the journal.)Joint Bone Spine is indexed in the main international databases and is accessible worldwide through the ScienceDirect and ClinicalKey platforms.